Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions

PLoS Computational Biology

Volumn 8, Issue 8, 2012, Pages

  Duke, Jon D ^a   Han, Xu ^b   Wang, Zhiping ^b   Subhadarshini, Abhinita ^b   Karnik, Shreyas D ^b   Li, Xiaochun ^b   Hall, Stephen D ^c   Jin, Yan ^c   Callaghan, J Thomas ^b   Overhage, Marcus J ^d   Flockhart, David A ^b,e   Strother, R Matthew ^b   Quinney, Sara K ^b,e   Li, Lang ^b,e  

^a REGENSTRIEF INSTITUTE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d SIEMENS CORPORATE RESEARCH   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITION; MEDICAL COMPUTING; METABOLISM; PHYSIOLOGY;

CLINICAL ASSESSMENTS; CYTOCHROMES P450; DRUG-DRUG INTERACTIONS; IN-VITRO; INTERACTION PREDICTION; MEDICAL RECORD; POTENTIAL DRUG; PROMETHAZINE; SIMVASTATIN; TEGASEROD;

DRUG INTERACTIONS;

ALPRAZOLAM; ATORVASTATIN; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DULOXETINE; GEMFIBROZIL; ITRACONAZOLE; KETOCONAZOLE; LORATADINE; MEVINOLIN; PRAVASTATIN; PROMETHAZINE; ROPINIROLE; SIMVASTATIN; TACROLIMUS; TEGASEROD;

ARTICLE; BIOINFORMATICS; CLINICAL ASSESSMENT; COMPUTER PREDICTION; DATA MINING; DRUG DRUG INTERACTION; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENTIATION; ELECTRONIC MEDICAL RECORD; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; MYOPATHY;

EID: 84866067701     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002614     Document Type: Article

References (25)

1. Becker LB, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, et al. (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16: 641-651.
2. Hamilton RA, Briceland LL, Andritz MH, (1998) Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 18: 1112-1120.
3. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA, (2003) Drug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity. JAMA 289: 1652-1658.
4. Jankel CA, Fitterman LK, (1993) Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 9: 51-59.
5. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, et al. (1995) Systems Analysis of Adverse Drug Events. JAMA 274: 35-43.
6. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, et al. (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48: 662-670.
7. Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, et al. (2010) Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 38: 241-248.
8. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, et al. (2011) Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study. Clin Pharmacol Ther 90: 575-581.
9. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, et al. (2008) Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 84: 581-588.
10. Tatonetti NP, Fernald GH, Altman RB, (2012) A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc 19: 79-85.
11. Wienkers LC, Heath TG, (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4: 825-833.
12. Schech S, Graham D, Staffa J, Andrade SE, Grenade L, et al. (2007) Risk factors for statin-associated rhabdomyolysisy. Pharmacoepidemio Drug Saf 16: 352-358.
13. Tari L, Anwar S, Liang S, Cai J, Baral C, (2010) Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics 26: i547-553.
14. Percha B, Garten Y, Altman RB, (2012) Discovery and explanation of drug-drug interactions via text mining. Pacific Symp Biocomput pp. 410-421.
15. Boyce R, Collins C, Horn J, Kale I, (2009) Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions. J Biomed Inform 42: 990-1003.
16. Segura-Bedmar I, Martínez P, de Pablo-Sánchez C, (2011) Using a shallow linguistic kernel for drug-drug interaction extraction. J Biomed Inform 44: 789-804.
17. Segura-Bedmar I MP, de Pablo-Sánchez C, (2011) A linguistic rule-based approach to extract drug-drug interactions from pharmacological documents. BMC Bioinformatics (suppl 2) pp. S1.
18. Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S, (2010) Anti-Infectives and the Risk of Severe Hypoglycemia in Users of Glipizide or Glyburide. Clin Pharmacol Ther 88: 214-222.
19. Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, et al. (2010) Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study. Pharmacotherapy 30: 787-796.
20. SEARCH Collaborative Group (2008) Link E, Parish S, Armitage J, Bowman L, et al. (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359: 789-799.
21. Hurst FP, Neff RT, Jindal RM, Roberts JR, Lentine KL, et al. (2009) Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation. Nephrol Dial Transplant 24: 3861-3866.
22. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, et al. (2010) Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy Implications for Risk Assessment, Prevention and Treatment. Drug Saf 33: 171-187.
23. Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, et al. (2010) Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 153: 600-606.
24. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39: D1035-41.
25. Wang K, Li M, Hakonarson H, (2010) Analysing biological pathways in genome-wide association studies. Nat Rev Genet 11: 843-854.